MarketPeel
Insider Trading Intelligence
Pricing
…
HR

Howard W. Robin

NKTR
PRESIDENT & CEO · NEKTAR THERAPEUTICS · CIK 0001206869
FILING MIX · LIFETIME29%/71%
BUYS
22
SELLS
54
TOTAL VALUE
$18.00M
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
59,545
AVG SELL PX
$13.49
TRADE KIND
SHOWING 76 / 76
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
45 backtested trades · 8 horizons · 37 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Howard W. Robin, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d45+40.00%+5.71%+0.46%+5.25%+1.23%2.32
14d45+42.22%+11.05%+0.70%+10.36%+7.19%2.73
30d45+46.67%+10.64%+0.26%+10.39%+4.18%1.95
60d45+42.22%+13.40%+2.55%+10.85%-0.94%1.68
90d45+44.44%+16.21%+4.57%+11.65%-1.03%1.60
180d45(1 pending)+52.27%+28.60%+7.88%+21.06%-19.98%1.45
1y45(15 pending)+63.33%+33.13%+16.82%+16.31%-63.59%0.58
2y45(21 pending)+83.33%+6.31%+25.54%-19.23%-95.41%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NKTR · 59,545 shares · as of Jun 17, 2026
0325,000650,000975,0001,300,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 22 buys / 54 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
5,500$60.81$334.5K59,545Jun 17, 2026Jun 18, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
4,500$61.65$277.4K55,045Jun 17, 2026Jun 18, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
4,697$60.71$285.2K65,045Jun 16, 2026Jun 18, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
5,303$59.97$318.0K69,742Jun 16, 2026Jun 18, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
444$65.51$29.1K75,045May 19, 2026May 21, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
423$73.00$30.9K75,489Feb 18, 2026Feb 20, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
86,667——86,667Dec 22, 2025Dec 23, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
21,667——75,912Dec 22, 2025Dec 23, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
2,207$54.28$119.8K54,245Nov 25, 2025Nov 25, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
12,170——12,170Nov 21, 2025Nov 25, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
7,110——56,452Nov 21, 2025Nov 25, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
2,100$45.16$94.8K53,908Sep 9, 2025Sep 11, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
2,156$47.49$102.4K50,552Sep 9, 2025Sep 11, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
1,200$46.41$55.7K52,708Sep 9, 2025Sep 11, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
1,210$48.18$58.3K49,342Sep 9, 2025Sep 11, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
2,226$38.82$86.4K57,144Sep 5, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
3,304$37.87$125.1K59,370Sep 5, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
1,136$39.89$45.3K56,008Sep 5, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
1,134$35.80$40.6K62,674Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
613$34.40$21.1K63,808Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
1,496$33.54$50.2K64,421Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
1,923$32.37$62.2K65,917Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
1,500$30.16$45.2K67,840Sep 2, 2025Sep 4, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
1,573$26.59$41.8K69,340Aug 19, 2025Aug 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
86,666——86,666Aug 19, 2025Aug 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
23,208$0.67$15.5K1,063,693May 19, 2025May 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
23,774$1.01$24.0K1,086,901Feb 19, 2025Feb 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
85,035$0.99$84.2K1,110,675Dec 18, 2024Dec 19, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
46,995$1.01$47.5K1,195,710Dec 17, 2024Dec 19, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
1,300,000——1,300,000Dec 13, 2024Dec 17, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
410,625——1,242,705Dec 13, 2024Dec 17, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
821,250——821,250Dec 13, 2024Dec 17, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
16,278$1.01$16.4K832,080Nov 19, 2024Nov 20, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
14,881$1.28$19.0K848,358Aug 19, 2024Aug 20, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
16,650$1.75$29.1K863,239May 17, 2024May 20, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
20,033$0.68$13.6K879,889Feb 20, 2024Feb 22, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
1,300,000——1,300,000Dec 13, 2023Dec 15, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
19,877$0.49$9.7K899,922Nov 17, 2023Nov 20, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
19,998$0.78$15.6K919,799Aug 16, 2023Aug 17, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
20,361$0.72$14.7K939,797May 16, 2023May 17, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
19,635$3.00$58.9K960,158Feb 16, 2023Feb 17, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
38,014$3.57$135.7K979,793Nov 16, 2022Nov 18, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
13,759$4.76$65.5K1,017,807Aug 16, 2022Aug 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
821,250——821,250Aug 15, 2022Aug 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
410,625——1,031,566Aug 15, 2022Aug 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
36,529$3.95$144.3K620,941May 16, 2022May 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
68,450——657,470May 15, 2022May 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
12,480$10.95$136.7K589,020Feb 16, 2022Feb 18, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
126,050——601,500Dec 16, 2021Dec 20, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
223,750——223,750Dec 16, 2021Dec 20, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
42,773$13.16$562.9K475,450Nov 16, 2021Nov 17, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
94,100——518,223Nov 15, 2021Nov 17, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
167,650——167,650Oct 12, 2021Oct 14, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
11,515$13.83$159.3K424,123Aug 16, 2021Aug 18, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
11,560$18.30$211.5K435,638May 17, 2021May 19, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
11,495$22.37$257.1K447,198Feb 16, 2021Feb 18, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASE
President & CEO
150,000$8.80$1.32M608,693Feb 4, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
91,863$20.10$1.85M516,830Feb 4, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
58,137$20.58$1.20M458,693Feb 4, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
150,000——0Feb 4, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASE
President & CEO
75,000$8.80$660.0K608,693Feb 3, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
75,000——0Feb 3, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASE
President & CEO
75,000$8.80$660.0K533,693Feb 3, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
150,000$19.72$2.96M458,693Feb 3, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
75,000——150,000Feb 3, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
9,900$20.84$206.3K459,293Feb 2, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
600$21.59$13.0K458,693Feb 2, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
139,500$19.69$2.75M469,193Feb 2, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASE
President & CEO
150,000$8.80$1.32M608,693Feb 2, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
150,000——75,000Feb 2, 2021Feb 4, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
106,650——458,693Dec 18, 2020Dec 22, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
190,650——190,650Dec 18, 2020Dec 22, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
11,975$16.93$202.7K352,043Nov 16, 2020Nov 18, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
11,885$19.67$233.8K364,018Aug 17, 2020Aug 19, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
8,968$22.51$201.9K375,903May 18, 2020May 20, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
President & CEO
8,448$22.35$188.8K384,871Feb 18, 2020Feb 20, 2020 ↗View →
Other insiders · NKTR
Loading peer insiders…
About this filer
CIK 0001206869
ROLE
President & CEO
PRIMARY
NKTR
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001206869DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback